schliessen

Filtern

 

Bibliotheken

Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience

Context: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAFV600E mutation. Objective: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. Design: A retrospectiv... Full description

Journal Title: The journal of clinical endocrinology and metabolism 2015, Vol.100 (1), p.E77-E81
Main Author: Dadu, Ramona
Other Authors: Shah, Komal , Busaidy, Naifa L , Waguespack, Steven G , Habra, Mouhammad A , Ying, Anita K , Hu, Mimi I , Bassett, Roland , Jimenez, Camilo , Sherman, Steven I , Cabanillas, Maria E
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Chevy Chase, MD: Endocrine Society
ID: ISSN: 0021-972X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4283003
title: Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience
format: Article
creator:
  • Dadu, Ramona
  • Shah, Komal
  • Busaidy, Naifa L
  • Waguespack, Steven G
  • Habra, Mouhammad A
  • Ying, Anita K
  • Hu, Mimi I
  • Bassett, Roland
  • Jimenez, Camilo
  • Sherman, Steven I
  • Cabanillas, Maria E
subjects:
  • Brief Reports
  • JCEM Online
ispartof: The journal of clinical endocrinology and metabolism, 2015, Vol.100 (1), p.E77-E81
description: Context: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAFV600E mutation. Objective: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. Design: A retrospective review at MD Anderson Cancer Center. Methods: The best responses were evaluated using RECIST v1.1. A single radiologist reviewed all images. Adverse events (AEs) were evaluated using CTCAE v.4.0. Results: We identified 17 patients with advanced PTC harboring the BRAFV600E mutation who were treated with vemurafenib outside of a clinical trial. Median age at diagnosis was 63 years, and 53% were male. At vemurafenib start, 3 (18%) patients had disease confined to the neck, and 14 (72%) had distant metastases. Tyrosine kinase inhibitors had been previously administered to 4 (24%) patients. Two (12%) patients discontinued vemurafenib because of AEs before restaging. Best response: partial response (PR) in 7/15 (47%) and stable disease (SD) in 8/15(53%) patients. The rate of durable response (PR plus SD ≥ 6 months) was 67%. Median time to treatment failure was 13 months. There was no association between change in thyroglobulin and tumor size. Drug discontinuation, drug interruptions, and dose reductions were needed in 5 (29%), 13 (76%), and 10 (59%) patients, respectively. Most common AEs were fatigue (71%), weight loss (71%), anorexia (65%), arthralgias (59%), hair loss (59%), rash (59%), hand-foot syndrome (53%), calluses (47%), diarrhea (47%), fever (41%), dry mouth (35%), nausea (35%), and verrucous keratosis (35%). Grade ≥ 3 AEs were present in 8 (47%) patients. Conclusions: Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAFV600E mutation. Our results are similar to those reported in a phase II clinical trial and support the potential role of vemurafenib in this patient population.
language: eng
source:
identifier: ISSN: 0021-972X
fulltext: no_fulltext
issn:
  • 0021-972X
  • 1945-7197
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6938326
LOCALfalse
PrimoNMBib
record
control
sourceidopenaire_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4283003
sourceformatXML
sourcesystemPC
sourcerecordidoai:dnet:od_______267::901544abdba1c4630c77487effddd9b3
originalsourceidFETCH-LOGICAL-13646-c08b6df9b34708919637e39032b8d9953709aab5b8dd2359d911915407b4ace0
addsrcrecordideNptke2KEzEUhgdR3HX1nxeQC3BqvmYy8YdQa9cVKrtIWfwX8nHGpk6TIZlu7Z14uaZ0ERYMhMNJ3vc5yTlV9ZbgGaEEv9_aGcWE15Ty9ll1SSRvakGkeF5dYkxJLQX9cVG9ynmLi4w37GV1QRvWMCzIZfVn2ffeantEOji0jgMkbfzgpyOKPbqH3T7pHoI3yAd0pycPYcro4KcN-vR9fn3fYrxE9V3MfvIPUBSjHwadjmi9OaboHVroYCF9QN9mn2doHhykHMPjKVoUWgm3fY9W2sCAlr9HSKWGhdfVi14PGd48xqtqfb1cL27q1e2Xr4v5qias5W1tcWda10vDuMCdJLJlApjEjJrOSdkwgaXWpimZo6yRThIiScOxMFxbwFfVxzN23JsdOFselPSgxuR35Rcqaq-e3gS_UT_jg-K0YxizArg5A-IIQfsET7wuwKSiU7QVSuJSl2vjjCaWtwxbIXgnoO-dc-UDBfXujLIp5pyg_4ciWJ1mrbZWnWatTrMucn6WH-JQuph_DfsDJLUBPUwbhcvirejqYmgwKVlddnOysbMNgos2-QBjgpzVNu5TKJ3-f7G_M367GA
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
display
typearticle
titleEfficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience
creatorDadu, Ramona ; Shah, Komal ; Busaidy, Naifa L ; Waguespack, Steven G ; Habra, Mouhammad A ; Ying, Anita K ; Hu, Mimi I ; Bassett, Roland ; Jimenez, Camilo ; Sherman, Steven I ; Cabanillas, Maria E
creatorcontribDadu, Ramona ; Shah, Komal ; Busaidy, Naifa L ; Waguespack, Steven G ; Habra, Mouhammad A ; Ying, Anita K ; Hu, Mimi I ; Bassett, Roland ; Jimenez, Camilo ; Sherman, Steven I ; Cabanillas, Maria E
descriptionContext: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAFV600E mutation. Objective: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. Design: A retrospective review at MD Anderson Cancer Center. Methods: The best responses were evaluated using RECIST v1.1. A single radiologist reviewed all images. Adverse events (AEs) were evaluated using CTCAE v.4.0. Results: We identified 17 patients with advanced PTC harboring the BRAFV600E mutation who were treated with vemurafenib outside of a clinical trial. Median age at diagnosis was 63 years, and 53% were male. At vemurafenib start, 3 (18%) patients had disease confined to the neck, and 14 (72%) had distant metastases. Tyrosine kinase inhibitors had been previously administered to 4 (24%) patients. Two (12%) patients discontinued vemurafenib because of AEs before restaging. Best response: partial response (PR) in 7/15 (47%) and stable disease (SD) in 8/15(53%) patients. The rate of durable response (PR plus SD ≥ 6 months) was 67%. Median time to treatment failure was 13 months. There was no association between change in thyroglobulin and tumor size. Drug discontinuation, drug interruptions, and dose reductions were needed in 5 (29%), 13 (76%), and 10 (59%) patients, respectively. Most common AEs were fatigue (71%), weight loss (71%), anorexia (65%), arthralgias (59%), hair loss (59%), rash (59%), hand-foot syndrome (53%), calluses (47%), diarrhea (47%), fever (41%), dry mouth (35%), nausea (35%), and verrucous keratosis (35%). Grade ≥ 3 AEs were present in 8 (47%) patients. Conclusions: Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAFV600E mutation. Our results are similar to those reported in a phase II clinical trial and support the potential role of vemurafenib in this patient population.
identifier
0ISSN: 0021-972X
1EISSN: 1945-7197
2DOI: 10.1210/jc.2014-2246
3PMID: 25353071
languageeng
publisherChevy Chase, MD: Endocrine Society
subjectBrief Reports ; JCEM Online
ispartofThe journal of clinical endocrinology and metabolism, 2015, Vol.100 (1), p.E77-E81
rights
0Copyright © 2015 by the Endocrine Society
1Copyright © 2015 by The Endocrine Society
2Copyright © 2015 by the Endocrine Society 2015
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-13646-c08b6df9b34708919637e39032b8d9953709aab5b8dd2359d911915407b4ace0
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
search
creatorcontrib
0Dadu, Ramona
1Shah, Komal
2Busaidy, Naifa L
3Waguespack, Steven G
4Habra, Mouhammad A
5Ying, Anita K
6Hu, Mimi I
7Bassett, Roland
8Jimenez, Camilo
9Sherman, Steven I
10Cabanillas, Maria E
title
0Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience
1The journal of clinical endocrinology and metabolism
descriptionContext: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAFV600E mutation. Objective: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. Design: A retrospective review at MD Anderson Cancer Center. Methods: The best responses were evaluated using RECIST v1.1. A single radiologist reviewed all images. Adverse events (AEs) were evaluated using CTCAE v.4.0. Results: We identified 17 patients with advanced PTC harboring the BRAFV600E mutation who were treated with vemurafenib outside of a clinical trial. Median age at diagnosis was 63 years, and 53% were male. At vemurafenib start, 3 (18%) patients had disease confined to the neck, and 14 (72%) had distant metastases. Tyrosine kinase inhibitors had been previously administered to 4 (24%) patients. Two (12%) patients discontinued vemurafenib because of AEs before restaging. Best response: partial response (PR) in 7/15 (47%) and stable disease (SD) in 8/15(53%) patients. The rate of durable response (PR plus SD ≥ 6 months) was 67%. Median time to treatment failure was 13 months. There was no association between change in thyroglobulin and tumor size. Drug discontinuation, drug interruptions, and dose reductions were needed in 5 (29%), 13 (76%), and 10 (59%) patients, respectively. Most common AEs were fatigue (71%), weight loss (71%), anorexia (65%), arthralgias (59%), hair loss (59%), rash (59%), hand-foot syndrome (53%), calluses (47%), diarrhea (47%), fever (41%), dry mouth (35%), nausea (35%), and verrucous keratosis (35%). Grade ≥ 3 AEs were present in 8 (47%) patients. Conclusions: Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAFV600E mutation. Our results are similar to those reported in a phase II clinical trial and support the potential role of vemurafenib in this patient population.
subject
0Brief Reports
1JCEM Online
issn
00021-972X
11945-7197
fulltextfalse
rsrctypearticle
creationdate2015
recordtypearticle
recordideNptke2KEzEUhgdR3HX1nxeQC3BqvmYy8YdQa9cVKrtIWfwX8nHGpk6TIZlu7Z14uaZ0ERYMhMNJ3vc5yTlV9ZbgGaEEv9_aGcWE15Ty9ll1SSRvakGkeF5dYkxJLQX9cVG9ynmLi4w37GV1QRvWMCzIZfVn2ffeantEOji0jgMkbfzgpyOKPbqH3T7pHoI3yAd0pycPYcro4KcN-vR9fn3fYrxE9V3MfvIPUBSjHwadjmi9OaboHVroYCF9QN9mn2doHhykHMPjKVoUWgm3fY9W2sCAlr9HSKWGhdfVi14PGd48xqtqfb1cL27q1e2Xr4v5qias5W1tcWda10vDuMCdJLJlApjEjJrOSdkwgaXWpimZo6yRThIiScOxMFxbwFfVxzN23JsdOFselPSgxuR35Rcqaq-e3gS_UT_jg-K0YxizArg5A-IIQfsET7wuwKSiU7QVSuJSl2vjjCaWtwxbIXgnoO-dc-UDBfXujLIp5pyg_4ciWJ1mrbZWnWatTrMucn6WH-JQuph_DfsDJLUBPUwbhcvirejqYmgwKVlddnOysbMNgos2-QBjgpzVNu5TKJ3-f7G_M367GA
startdate201501
enddate201501
creator
0Dadu, Ramona
1Shah, Komal
2Busaidy, Naifa L
3Waguespack, Steven G
4Habra, Mouhammad A
5Ying, Anita K
6Hu, Mimi I
7Bassett, Roland
8Jimenez, Camilo
9Sherman, Steven I
10Cabanillas, Maria E
general
0Endocrine Society
1Copyright by The Endocrine Society
scope
0AAYXX
1CITATION
2BOBZL
3CLFQK
45PM
sort
creationdate201501
titleEfficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience
authorDadu, Ramona ; Shah, Komal ; Busaidy, Naifa L ; Waguespack, Steven G ; Habra, Mouhammad A ; Ying, Anita K ; Hu, Mimi I ; Bassett, Roland ; Jimenez, Camilo ; Sherman, Steven I ; Cabanillas, Maria E
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-13646-c08b6df9b34708919637e39032b8d9953709aab5b8dd2359d911915407b4ace0
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Brief Reports
1JCEM Online
toplevelpeer_reviewed
creatorcontrib
0Dadu, Ramona
1Shah, Komal
2Busaidy, Naifa L
3Waguespack, Steven G
4Habra, Mouhammad A
5Ying, Anita K
6Hu, Mimi I
7Bassett, Roland
8Jimenez, Camilo
9Sherman, Steven I
10Cabanillas, Maria E
collection
0CrossRef
1OpenAIRE (Open Access)
2OpenAIRE
3PubMed Central (Full Participant titles)
jtitleThe journal of clinical endocrinology and metabolism
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Dadu, Ramona
1Shah, Komal
2Busaidy, Naifa L
3Waguespack, Steven G
4Habra, Mouhammad A
5Ying, Anita K
6Hu, Mimi I
7Bassett, Roland
8Jimenez, Camilo
9Sherman, Steven I
10Cabanillas, Maria E
formatjournal
genrearticle
ristypeJOUR
atitleEfficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience
jtitleThe journal of clinical endocrinology and metabolism
date2015-01
risdate2015
volume100
issue1
spageE77
epageE81
pagesE77-E81
issn0021-972X
eissn1945-7197
notesThis work was supported by the NIH/NCI under Award No. P30CA016672.
abstractContext: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAFV600E mutation. Objective: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. Design: A retrospective review at MD Anderson Cancer Center. Methods: The best responses were evaluated using RECIST v1.1. A single radiologist reviewed all images. Adverse events (AEs) were evaluated using CTCAE v.4.0. Results: We identified 17 patients with advanced PTC harboring the BRAFV600E mutation who were treated with vemurafenib outside of a clinical trial. Median age at diagnosis was 63 years, and 53% were male. At vemurafenib start, 3 (18%) patients had disease confined to the neck, and 14 (72%) had distant metastases. Tyrosine kinase inhibitors had been previously administered to 4 (24%) patients. Two (12%) patients discontinued vemurafenib because of AEs before restaging. Best response: partial response (PR) in 7/15 (47%) and stable disease (SD) in 8/15(53%) patients. The rate of durable response (PR plus SD ≥ 6 months) was 67%. Median time to treatment failure was 13 months. There was no association between change in thyroglobulin and tumor size. Drug discontinuation, drug interruptions, and dose reductions were needed in 5 (29%), 13 (76%), and 10 (59%) patients, respectively. Most common AEs were fatigue (71%), weight loss (71%), anorexia (65%), arthralgias (59%), hair loss (59%), rash (59%), hand-foot syndrome (53%), calluses (47%), diarrhea (47%), fever (41%), dry mouth (35%), nausea (35%), and verrucous keratosis (35%). Grade ≥ 3 AEs were present in 8 (47%) patients. Conclusions: Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAFV600E mutation. Our results are similar to those reported in a phase II clinical trial and support the potential role of vemurafenib in this patient population.
copChevy Chase, MD
pubEndocrine Society
pmid25353071
doi10.1210/jc.2014-2246
oafree_for_read